| __timestamp | Takeda Pharmaceutical Company Limited | Verona Pharma plc |
|---|---|---|
| Wednesday, January 1, 2014 | 612613000000 | 1802274 |
| Thursday, January 1, 2015 | 650773000000 | 2512761 |
| Friday, January 1, 2016 | 619061000000 | 2894488 |
| Sunday, January 1, 2017 | 628106000000 | 8096274 |
| Monday, January 1, 2018 | 717599000000 | 7985229 |
| Tuesday, January 1, 2019 | 964737000000 | 8994597 |
| Wednesday, January 1, 2020 | 875663000000 | 29772000 |
| Friday, January 1, 2021 | 886361000000 | 33907000 |
| Saturday, January 1, 2022 | 997309000000 | 26579000 |
| Sunday, January 1, 2023 | 1053819000000 | 49868547 |
| Monday, January 1, 2024 | 1053819000000 |
Unleashing the power of data
In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Takeda Pharmaceutical Company Limited and Verona Pharma plc offer a fascinating contrast in this regard. Over the past decade, Takeda has consistently reported SG&A expenses that dwarf those of Verona Pharma, with figures reaching over 1 trillion yen by 2023. This represents a growth of approximately 72% since 2014. In contrast, Verona Pharma's SG&A expenses have grown from a modest 1.8 million pounds in 2014 to nearly 50 million pounds in 2023, marking a staggering increase of over 2,600%.
While Takeda's expenses reflect its expansive global operations, Verona's rapid growth highlights its aggressive market entry strategy. However, data for 2024 is incomplete, leaving room for speculation on future trends. This analysis underscores the diverse strategies companies employ to navigate the competitive pharmaceutical landscape.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Verona Pharma plc
Selling, General, and Administrative Costs: Johnson & Johnson vs Verona Pharma plc
Who Optimizes SG&A Costs Better? AbbVie Inc. or Verona Pharma plc
SG&A Efficiency Analysis: Comparing Novartis AG and Verona Pharma plc
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
Verona Pharma plc and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Verona Pharma plc and Xenon Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? Verona Pharma plc or MorphoSys AG
Comparing SG&A Expenses: Verona Pharma plc vs MiMedx Group, Inc. Trends and Insights